Follow Us Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Commercial Law Litigation Products Liability

Off-Label Promotion and Product Liability Considerations

An update on the current regulatory landscape in the off-label promotional area and also review potential liability risks for companies to consider, and recommendations to reduce these risks.


Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Much has been written, including by us in January 2016, about the Food and Drug Administration’s (FDA’s) court losses in the area of off-label promotion (e.g., promotion of a pharmaceutical product’s unapproved uses). The agency held a public meeting in November 2016, and it is unclear how and when the FDA will issue any guidance, if at all, on its enforcement policy toward off-label promotion. Nevertheless, companies must remember that the agency will continue to take enforcement action, as appropriate, and FDA enforcement letters are made publicly available on its website. As such, non-compliance with FDA rules increases product liability exposure. In addition, even if the agency does not act, inaction does not preclude a product liability claim if someone is injured as a result of an unapproved use promoted by the company.

To continue reading,
become a free ALM digital reader

Benefits include:

*May exclude premium content

Read These Next